NRx Pharmaceuticals (NRXP) earnings
NRx Pharmaceuticals earnings: last reported Mon, 17 Aug 2026, for the quarter ended Jun 2026.
NRx Pharmaceuticals earnings callsNRx Pharmaceuticals earnings calls (NRXP)
NRx Pharmaceuticals Q2 FY26 — Pipeline Advancement and Strategic Partnerships
What went well
- ANDA for preservative-free ketamine resolved its single major deficiency and aims for 2026 approval, with 5 million units of launch stock ordered.
- NRX-100 NDA is poised for finalization, aiming for 2027 approval, supported by White House and Congressional guidance on real-world evidence.
- NRX-101 market expanded to treatment-resistant depression through a DARPA-selected prime contract for the SPARC-TMS trial, targeting over 15 million Americans.
What to watch
- Net operating loss increased to $11.3 million for the first half of FY26, compared to $7.6 million in the prior year, driven by increased R&D and SG&A for anticipated commercial launches.
Performance −10.2% 1Y
1Y: $3.25 on 29 Sept 2025 → $2.92. High $4.62 (1 Jun 2026), low $1.68 (5 Feb 2026).
Quarterly results
Q2 FY26: net profit up 6.0% against the same quarter last year.
| Line item | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | — | 0 | 0 | 0 | 1 | 1 | 1 |
| EBITDA | -3 | -2 | -4 | -4 | -4 −33% | -5 −90% | -5 −23% | -7 −74% |
| Net profit | -2 | -9 | -6 | -18 | -6 −263% | 0 +104% | -1 +74% | -17 +6% |
How to read this
US$ million, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Balance sheet
| Year ending | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | $43.0K | $59.0K | $67.0K | $8.0K | $15.0K | $32.0K |
| Reserves | -$90.18M | -$183.24M | -$223.00M | -$253.15M | -$278.27M | -$306.89M |
| Total liabilities | $46.71M | $11.92M | $18.41M | $19.05M | $26.87M | $28.89M |
| Fixed assets | — | — | — | — | $10.0K | $63.0K |
| Total assets | $2.94M | $32.73M | $25.82M | $7.32M | $3.65M | $12.96M |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of NRXP filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.